Details for Patent: 8,052,994
✉ Email this page to a colleague
Which drugs does patent 8,052,994 protect, and when does it expire?
Patent 8,052,994 protects PROMACTA and is included in one NDA.
Protection for PROMACTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has sixty-six patent family members in thirty-four countries.
Summary for Patent: 8,052,994
| Title: | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| Abstract: | Disclosed are novel pharmaceutical compositions containing 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-- ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same. |
| Inventor(s): | Muller; Francis X. (King of Prussia, PA), Kapsi; Shivakumar G. (King of Prussia, PA) |
| Assignee: | GlaxoSmithKline LLC (Philadelphia, PA) |
| Application Number: | 12/607,305 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,052,994 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Dosage form; Process; Use; |
More… ↓ |
Drugs Protected by US Patent 8,052,994
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-004 | Oct 20, 2011 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Novartis | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-001 | Nov 20, 2008 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Novartis | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-002 | Nov 20, 2008 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Novartis | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-003 | Sep 8, 2009 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,052,994
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 059656 | ⤷ Subscribe | |||
| Argentina | 107711 | ⤷ Subscribe | |||
| Australia | 2007352608 | ⤷ Subscribe | |||
| Brazil | PI0721651 | ⤷ Subscribe | |||
| Canada | 2685831 | ⤷ Subscribe | |||
| Chile | 2007002242 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
